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y of Cair
osting by EAbstract Ratio subtraction and isosbestic point methods are two innovative spectrophotometric
methods for determining the concentrations of metronidazole (I) and diloxanide furoate (II) in a
mixture. Metronidazole was determined by direct spectrophotometric method at kmax 314.0 nm in
the presence of diloxanide furoate in the range of 4–24 lg ml1 with a mean recovery percentage
of 99.83 ± 1.41. Two spectrophotometric methods were developed for the spectral resolution of
diloxanide furoate when present in mixture with metronidazole without preliminary separation.
The ﬁrst method depends on measuring the absorbance at the isosbestic point at 277.2 nm in the
range of 5–30 lg ml1 with a mean recovery percentage of 99.96 ± 1.47 for diloxanide furoate.
The second method is the ratio subtraction spectroscopic method for spectral isolation of diloxanide
furoate present in the mixture which can be measured at 251.2 nm in the range of 5–30 lg ml1 with a
mean recovery percentage of 99.73 ± 1.33 for diloxanide furoate determination. The suggested pro-
cedures were validated using laboratory-prepared mixtures and were successfully applied for the
analysis of pharmaceutical preparations. The methods retained their accuracy and precision when
the standard addition technique was applied. The results obtained by applying the proposed methods
were statistically analyzed and compared with those obtained by the reported method.
ª 2010 Cairo University. Production and hosting by Elsevier B.V. All rights reserved.020604.
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lsevierIntroduction
Metronidazole and diloxanide furoate are formulated together
to be highly effective in the treatment of intestinal and extrain-
testinal amoebic infections. Metronidazole is less effective
against parasites in the bowel lumen and is, therefore, used
in combination with a luminal amoebicide, such as diloxanide
furoate in the treatment of invasive amoebiasis.
Metronidazole 2-methyl-5-nitroimidazole-1-ethanol [1]
was determined individually by short-wave length NIR
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gas chromatography [7] and HPLC methods either alone
[8–10] or in the presence of its metabolites [11,12] or in the
presence of its degradation product [13], in addition to its mix-
ture with other drugs [14,15]. First derivative spectrophotom-
etry was used for the determination of metronidazole in
mixture with ciproﬂoxacin [16].
Diloxanide furoate 2,2-dichloro-N-(4-hydroxyphenyl)-
N-methylacetamide [1] was determined individually by colori-
metric method [17], in the presence of its degradation product
by derivative technique, derivative ratio, TLC-densitometry
[18] and HPLC [18,19] and in mixture with tinidazole and fura-
zolidone by second derivative spectrophotometry [20].
The main problem of spectrophotometric binary mixture
analysis is the simultaneous determination of the two com-
pounds in the same mixture without prior separation. One
spectrophotometric determination method has been used for
resolving such mixture with overlapping spectra, derivative
spectrophotometry [21] and HPLC [22].
The aim of this work is to develop new spectrophotometric
methods for resolving this mixture with spectral interfering
problems, without preliminary separation. The new methods
were very simple, did not require any computer programs
(derivative and derivative ratio) as metronidazole was deter-
mined by direct spectrophotometry and diloxanide furoate
was determined by simple mathematical calculation. Also the
method used did not require any sophisticated instrumentation,
such as HPLC, which requires solvents and time.
Experimental
Apparatus
Spectrophotometer: SHIMADZU UV-1601 PC, dual beam
UV–visible spectrophotometer with two matched 1 cm quartz
cells, connected to an IBM compatible personal computer
(PC) and an HP-600 inkjet printer. Bundled UV-PC personal
spectroscopy software version (3.7) was used to process the
absorption and the derivative spectra. The spectral band width
was 0.2 nm with wavelength scanning speed of 2800 nm min1.Materials
Pure samples
Metronidazole and diloxanide furoate were kindly supplied by
Egyptian Int. Pharmaceutical Industries Co., E.I.P.I.CO. 10th
of Ramadan City, Area B1 P.O. 149, Egypt. Their purity was
found to be 99.84 ± 1.26 and 100.50 ± 0.71, respectively,
according to the manufacturer’s direct spectrophotometric
method (personal communication).
Market samples
Furazole tablets (E.I.P.I.CO.); batch no. 080435. It was labeled
to contain 200 and 250 mg metronidazole and diloxanide furo-
ate, respectively, per tablet.
Furazole suspension (E.I.P.I.CO.); batch no. 074135. It was
labeled to contain 200 and 100 mg metronidazole and diloxa-
nide furoate, respectively, per 5 ml.Chemicals and reagents
All chemicals were of analytical grade and the solvents were of
spectroscopic grade. Methanol, (E-Merck, Darmstadt,
Germany).
Standard solutions
Stock solutions
Metronidazole (I) and diloxanide furoate (II) stock solutions
(1 mg ml1) were prepared by weighing accurately 100 mg of
each powder into two separate 100 ml volumetric ﬂasks. Meth-
anol (50 ml) was added, shaken for a few minutes and com-
pleted to volume with the same solvent.
Working solutions
Four micro litres of the stock solution of (I) and 5 ml of the
stock solution (II) were accurately transferred into two sepa-
rate 50 ml measuring ﬂasks and diluted to the mark with meth-
anol to get a ﬁnal concentration of 80 lg ml1 and 100 lg ml1
of (I) and (II), respectively.
Laboratory-prepared mixtures
Accurate aliquots equivalent to (40–100 lg) of (I) were trans-
ferred from its working solution (80 lg ml1) into a series of
10 ml volumetric ﬂasks and portions equivalent to (50–
150 lg) of (II) from its working solution (100 lg ml1) were
added to the same ﬂasks and volumes were completed to mark
with methanol and mixed well.
Procedures
Isosbestic spectrophotometric method
Linearity: aliquots from (I) and (II) working solutions (80 lg ml
1 of (I) and 100 lg ml1 of (II), respectively) equivalent to 40–
240 lg of (I) and 50–300 lg of (II) were transferred into two sep-
arate sets of 10 ml volumetric ﬂasks and completed to the mark
with methanol. The zero order absorption spectra were re-
corded for both drugs using methanol as a blank; then the
absorbance was measured at 314.0 nm for (I) and 277.2 nm
(Aiso) for (I) and (II). Two calibration curves were constructed
for each drug relating the absorbance at the selected wavelength
to the corresponding drug concentrations and the regression
equations were computed.
Assay of laboratory-prepared mixtures: Absorbance of the
spectra of laboratory-prepared mixtures containing different
ratios of (I) and (II) were measured at 314.0 nm corresponding
to the contents of (I) only, and at 277.2 nm (Aiso) correspond-
ing to the total content of (I) and (II) in the mixture. The con-
centration of (I) alone and the total concentration of the two
drugs were calculated from their corresponding regression
equations; then by subtraction of (I) concentration from the
total mixture concentration, yielding the actual concentration
of (II) in the mixture.
Ratio subtraction spectrophotometric method
Linearity: Aliquots containing 50–300 lg from (II) working
solution (80 lg ml1) were transferred into a series of 10 ml
volumetric ﬂasks then completed to volume with methanol;
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calibration curve was constructed relating the absorbance of
zero order spectra of (II) at kmax 251.2 nm to the correspond-
ing concentrations and the regression equation was computed.
Aliquot equivalent to 40 lg from the (I) working solution
(100 lg ml1) was transferred into 10 ml volumetric ﬂask and
completed to volume with methanol to be used as a divisor
(4 lg ml1).
Assay of laboratory-prepared mixtures: Absorbance of the
spectra of laboratory-prepared mixtures containing different
ratios of (I) and (II) was scanned; then the (absorbance at each
wavelength) was divided by the spectrum of 4 lg ml1of stan-
dard (I) (divisor) to obtain division spectra and the absorbance
in the plateau region (the constant) was subtracted. By multi-
plication of the obtained spectra (absorbance at each wave-
length) by the spectrum of the divisor the original curves for
direct determination of (II) at 251.2 nm were obtained and
the concentration was calculated from the corresponding
regression equation.Assay of pharmaceutical formulations
Furazole tablets: Ten Furazole tablets were accurately weighed
and ﬁnely powdered. A portion equivalent to 8 mg of (I) and
10 mg of (II) was weighed. The powder was transferred intoFig. 1 Zero order absorption spectra of 20 lg ml1 of metronidazole
containing 10 lg ml1 of each (. . . . . ..) using methanol as a blank.
Table 1 Method validation for the determination of pure sample of
Parameter Isosbestic spectrophotometry
Metronidazole D
Accuracy mean ± SD 99.83 ± 1.41 9
Precision repeatabilitya 100.07 ± 0.76 9
Intermediate precisionb 99.95 ± 0.82 1
Concentration range (lg ml1) 4–24 5
a The intraday (n= 3), average of three concentrations (4, 12, 24 lg m
repeated three times within the day.
b The interday (n= 3), average of three concentrations (4, 12, 24 lg m
repeated three times in three successive days.a 100 ml beaker, sonicated in 20 ml methanol for 10 min and
ﬁltered into a 100 ml volumetric ﬂask. The residue was washed
three times using 20 ml methanol each time and the volume
was completed to the mark with methanol. Aliquots of 0.5, 1
and 1.5 ml were separately transferred to 10 ml volumetric
ﬂask and diluted with methanol. The general procedures under
linearity were followed.
The validity of the methods was assessed by applying the
standard addition technique.
Furazole suspension: Furazole (0.5 ml) suspension was accu-
rately transferred into a 100 ml beaker, sonicated in 20 ml
methanol for 10 min and ﬁltered into a 100 ml volumetric ﬂask.
The residue was washed using 20 ml methanol and the volume
was completed to the mark with methanol. Aliquots of 0.2, 0.4
and 0.6 ml (for analysis of metronidazole) and 0.5, 1 and 1.5 ml
(for analysis of diloxanide furoate) were separately transferred
to 10 ml volumetric ﬂasks and diluted with methanol. The gen-
eral procedures under linearity were followed.
The validity of the methods was assessed by applying the
standard addition technique.Results and discussion
Analytical methods for the determination of binary mixture
without previous separation were of interest. Metronidazole(_____), 20 lg ml1 of diloxanide furoate (- - - - -) and (1:1) mixture
metronidazole and diloxanide furoate by the proposed methods.
Ratio subtraction spectrophotometry
iloxanide furoate Diloxanide furoate
9.96 ± 1.47 99.73 ± 1.33
9.93 ± 0.48 99.87 ± 0.52
00.05 ± 0.60 100.11 ± 0.59
–30 5–30
l1) for metronidazole and (5, 15, 25 lg ml1) for diloxanide furoate
l1) for metronidazole and (5, 15, 25 lg ml1) for diloxanide furoate
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314.0 nm, while the absorption spectra of diloxanide furoate
and metronidazole showed severe overlap, which makes the
determination of diloxanide furoate concentration in the mix-
ture more difﬁcult (Fig. 1). By applying the proposed tech-
niques to the spectral data of the mixture, both diloxanide
furoate and metronidazole concentrations could be determined
without any interference.
Isosbestic spectrophotometric method
Erram and Tipnis [23] developed the isosbestic spectrophoto-
metric method. This method was used for simultaneous deter-
mination of (I) and (II) in their binary mixtures. At the
isosbestic point the mixture of drugs acts as a single compo-
nent and gives the same absorbance value as pure drug. Thus,
by measuring the absorbance value at the chosen isosbestic
point 277.2 nm (Aiso) (Fig. 1), the total concentration of both
(I) and (II) could be calculated, while the concentration of (I)Table 2 Determination of metronidazole and diloxanide furoate in
Mixture no. Claimed taken (lg ml1) Isospest
Metronidazole Diloxanide
furoate
Metroni
Recover
at 314 n
1 10 8 101.61
2 10 10 98.71
3 10 5 101.57
4 5 8 97.30
5 15 8 100.77
6 5 10 98.18
Mean ± SD 99.69 ±
a Average of three determinations.
Fig. 2 Division spectra of laboratory prepared mixtures of dilo
metronidazole (Y’) as a divisor and methanol as a blank.in the mixture could be calculated, without any interference, at
314.0 nm. Thus the concentration of (II) could be calculated by
subtraction.
A linear correlation was obtained between the absorbance
values and the corresponding concentrations of both drugs at
their corresponding wavelengths. The regression equations
were:
Aiso ¼ 0:0134Cþ 0:0204 r ¼ 0:9994 at 277:2nm
A ¼ 0:0324Cþ 0:0024 r ¼ 0:9995 at 314:0nm
where A is the absorbance, C is the concentration of the drug
in lg ml1 and r is the correlation coefﬁcient.
The proposed method was applied for the determination of
(I) and (II) in bulk powder: satisfactory results were obtained
(Table 1).
The laboratory-prepared mixtures were analyzed by
the isosbestic method. The method is valid for determining
the drug in laboratory-prepared mixtures as shown in
(Table 2).laboratory-prepared mixtures by the proposed methods.
ic spectrophotometry Ratio subtraction
spectrophotometry
dazole Diloxanide furoate Diloxanide furoate
ya%
m
Recoverya% at
277.2 nm
Recoverya% at 251.2 nm
99.00 99.08
97.26 100.52
100.86 99.35
97.45 98.95
100.29 100.26
97.07 99.47
1.86 98.66 ± 1.65 99.61 ± 0.64
xanide furoate (X) and metronidazole (Y) using 4 lg ml1 of
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The method was applied for determination of mixture of (II)
and (I) when the spectrum of (I) extended than the other
(II), as shown in (Fig. 1). The determination of (II) could be
achieved by scanning the zero order absorption spectra of
the laboratory-prepared mixtures (I and II) in methanol, then
dividing them by a carefully chosen concentration (4 lg ml1)
of standard (I) (I0 = divisor) to produce a new ratio spectra
that represents II/I0 + constant, as shown in (Fig. 2); then,
subtraction of the absorbance values of these constants (I/I0)
in plateau as shown in (Fig. 3) followed by multiplication of
the obtained spectra by (I0) the divisor as shown in (Fig. 4); ﬁ-
nally, the original spectra of (II), which are used for direct
determination of (II) at 251.2 nm, could be obtained and theFig. 3 Division spectra of laboratory prepared mixtures of dilo
metronidazole (Y0) as a divisor and methanol as a blank after subtrac
Fig. 4 The zero order absorption spectra of diloxanide furoate obta
laboratory prepared mixtures after multiplication by the divisor (Y0).concentration from the corresponding regression equation
could be calculated. This can be summarized as follows:
ðIIþ IÞ=I0 ¼ II=I0 þ I=I0 ¼ II=I0 þ constant
II=I0 þ constant constant ¼ II=I0
II=I0  I0 ¼ II
The constant can be determined directly from the curve
(II + I)/I0 by the straight line which is parallel to the wave-
length axis in the region where (I) is extended. The correct
choice of the divisor is fundamental, as, if the concentration
of the divisor increases or decreases, the resulting constant va-
lue will be proportionally decreased or increased [24].
A linear correlation was obtained between the absorbance
and the corresponding concentration of (II) at its correspond-
ing wavelength: the regression equation was:xanide furoate (X) and metronidazole (Y) using 4 lg ml1 of
tion of the constant.
ined by the proposed ratio subtraction method for the analysis of
Table 3 Determination of metronidazole and diloxanide furoate in their pharmaceutical preparations by the proposed methods and
application of standard addition technique.
Product Isosbestic spectrophotometry Ratio subtraction spectrophotometry
Founda (%) ± SD Added Founda Recovery (%) Founda (%) ± SD Added Founda Recovery (%)
Metronidazole in Furazole tablets
(batch no. 080435)
4 3.94 98.50 4 3.94 98.50
100.23 ± 0.62 8 8.03 100.38 100.23 ± 0.62 8 8.03 100.38
12 11.77 98.08 12 11.77 98.08
Mean ± SD 98.99 ± 1.23 98.99 ± 1.23
Diloxanide furoate in Furazole tablets
(batch no. 080435)
5 4.98 99.60 5 4.96 99.20
99.04 ± 0.98 10 9.81 98.10 98.97 ± 0.23 10 9.86 98.60
15 14.68 97.87 15 14.80 98.67
Mean ± SD 98.52 ± 0.94 98.82 ± 0.33
Metronidazole in Furazole suspension
(batch no. 074135)
4 3.95 98.75 4 3.95 98.75
98.69 ± 0.54 8 7.87 98.38 98.69 ± 0.54 8 7.87 98.38
12 11.90 99.17 12 11.90 99.17
Mean ± SD 98.77 ± 0.40 98.77 ± 0.40
Diloxanide furoate in Furazole
suspension (batch no. 074135)
5 4.98 99.60 5 4.97 99.40
99.20 ± 0.66 10 10.01 100.10 99.13 ± 0.49 10 9.96 99.60
15 14.72 98.13 15 15.08 100.53
Mean ± SD 99.28 ± 1.02 99.84 ± 0.60
a Average of three determinations.
Table 4 Statistical comparison of the results obtained by applying the proposed methods and the direct spectrophotometric
manufacturer method for the analysis of pure metronidazole and diloxanide furoate.
Manufacturer method Ratio subtraction spectrophotometry Isosbestic spectrophotometry Value
Diloxanide furoate Metronidazole Diloxanide furoate Diloxanide furoate Metronidazole
100.50 99.84 99.73 99.96 99.83 Mean
0.71 1.26 1.33 1.47 1.41 SD
6 6 6 6 6 n
0.504 1.588 1.769 2.161 1.988 Variance
– – 1.251 0.816 0.013 t-Test (2.228)*
– – 3.510 4.288 1.252 F value (5.05)*
* The values in parenthesis are corresponding to the theoretical values of t and F (P= 0.05).
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where A is the absorbance of (II) at 251.2 nm, C is the concen-
tration of (II) in lg ml1 and r is the correlation coefﬁcient.
The proposed method was applied for the determination of
(II) in bulk powder and satisfactory results were obtained see
(Table 1).
The laboratory-prepared mixtures were analyzed by the ra-
tio subtraction method at 251.2 nm. The method is valid for
determining the drug in laboratory-prepared mixtures as
shown in (Table 2).
The proposed methods were successfully applied for the
analysis of both drugs in pharmaceutical dosage form and
the results are shown in (Table 3).
The validity of the proposed methods was assessed by
applying the standard addition technique. The results obtained
were reproducible with low relative standard deviation as
shown in (Table 3).
A statistical comparison of the results obtained by the two
proposed methods and the manufacturer’s method for pure
drugs is shown in Table 4. The values of the calculated t and
F are less than the tabulated ones, which reveals that there is
no signiﬁcant difference with respect to accuracy and precisionbetween the proposed methods and the manufacturer’s
procedure.
Conclusion
The aim of this work is to develop simple and new methods for
the simultaneous determination of metronidazole and diloxa-
nide furoate. The isosbestic spectrophotometric and ratio sub-
traction spectrophotometric methods could be applied to the
simultaneous determination of metronidazole and diloxanide
furoate either in their pure powder form or in their combined
preparations. The results demonstrate the usefulness of the
methods, which are simple, safe, sensitive, precise, accurate,
inexpensive and non-polluting. So, the proposed methods
could be used in routine and quality control analysis of metro-
nidazole and diloxanide furoate in pharmaceutical prepara-
tions containing them.
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